Treatment with Nerivio, an FDA-approved remotely controlled electrical neuromodulation device, may be more effective than standard medications in adolescents with migraines, according to a post-hoc analysis.
Nerivio is a wireless remote controlled electrical neuromodulation device approved for the acute treatment of episodic or chronic migraines in patients 12 years and older. The device is self-placed on the upper arm and uses electrical impulses to stimulate the nociceptive sensory fibers C and Aδ to activate the brain’s conditioned pain modulation response to treat pain and migraine symptoms.
The 2-month comparative analysis comprised 35 patients between the ages of 12 and 17 years with chronic and episodic migraines. Pain relief and pain relief results were compared between a run-in phase in which migraine attacks were treated with oral triptans and over-the-counter drugs for 1 month and an intervention phase in which the attacks were treated with Nerivio for 1 month. The effectiveness was assessed 2 hours after treatment with the McNemar test.
Continue reading
The results showed that 37.1% of patients treated with Nerivio achieved freedom from pain 2 hours after treatment, compared with 8.6% of patients treated with standard treatment (P = 0.004). In addition, a greater proportion of patients treated with Nerivio achieved pain relief compared to those receiving medication (71.4% vs. 57.1%; P = 0.225).
Consistent freedom from pain and pain relief (defined as response to ³50% of the available first 4 treatments) were achieved by 40% and 80% of Nerivio-treated patients, respectively, compared with 8.6% (P <0.001) and 57.2% (P = .033) of those receiving standard care.
“To the best of my knowledge, this is the first study that directly compared remote electrical neuromodulation and standard treatment options in adolescents,” said Andrew D. Hershey, MD, PhD, co-director of the Headache Center and endowed professor and director of the Department of Neurology at Cincinnati Children’s Hospital Medical Center, who was the lead researcher on the study and lead author of the article. “Providing teens with more effective and engaging treatments for migraines can have far-reaching positive effects over the course of their lives.”
References
- Study compares Nerivio® with standard drugs for the acute treatment of migraines in adolescents. [press release]. Netanya, Israel and Montclair, NJ: Theranica; 06/30/2021.
- Hershey AD, Irwin S, Rabany L, et al. Comparison of remote electric neuromodulation (REN) and standard drugs for the acute treatment of migraine in adolescents: a post hoc analysis. Painkiller. Published online June 29, 2021. doi: 10.1093 / pm / pnab197
This article originally appeared on MPR
Subjects:
Migraines Migraines and Headache Pain Management Pediatric Neurology Treatments
